Cyto Wave Technologies’ iV3 device can detect circulating tumor cells in real time via laser technology and potentially destroy cells. OneMedRadio spoke with Cyto Wave Technologies President and CEO George Yu about the favorable on-ramp to commercialization, clearing regulatory and reimbursement obstacles and the vast opportunity for in vivo CTC detection.
On April 2nd, 2013, U.S. President Barack Obama unveiled the “BRAIN” Initiative, which is short for Brain Research through Advancing Innovative Neurotechnologies. The BRAIN Initiative may be known as the spiritual successor to the Human Genome Project, not only for its desire to understand a mysterious place known to medical science, but for taking its cues from the initial success of the HGP.
Atossa Genetics believes it can prevent breast cancer by 2020 — and in the meantime, capture a unique market opportunity — with their novel cellular and molecular diagnostic risk assessment products for early detection. Yet in a burgeoning diagnostics space, and rapid advancement in cancer therapeutics, will this company find a niche?
Amarantus Bioscience has posted a White Paper exploring the company’s LymPro Alzheimer’s Disease diagnostic, prepared by a member of the company’s Board of Advisors. The Paper discusses the increasing prevalence of Alzheimer’s disease, the clinical and economic advantages of early detection, and why the LymPro Test is poised to potentially become the market leading diagnostic product in the Alzheimer’s space.
Montreal-based Caprion has established itself as a leader in the proteomic biomarker discovery field, using its proteomics discovery platform CellCarta® to develop pharmacodynamic biomarkers, disease markers and predictive biomarkers. OneMedRadio spoke with Caprion President and CEO Martin Leblanc about industry trends concerning increased risk factors, securing intellectual property and developing an in vitro diagnostics platform.
The “elephant in the room” is the shifting, uncertain complexity of our regulatory and legislative environment. Exactly to that point, on Wednesday, March 27th Dr. Scott Gottlieb, a Forbes contributor focusing on policy, regulation, and public health posted an article entitled “Medicare Has Stopped Paying Bills For Medical Diagnostic Tests. Patients Will Feel”, which instantly caused a collective shiver among some diagnostics-focused investors and advisory groups. Experts shared their views on the Forbes article and its implications with us.
As we approach mid-year, many questions raised in the past year surrounding the state of healthcare company growth development have yet to be answered. The […]
GlySure Limited, developer of in-hospital continuous blood glucose monitoring systems, today announced that it has achieved ISO 13485 certification, the global standard for the requirements of a quality management system for the design, manufacture and distribution of medical devices. By establishing a quality management system that meets international regulatory and customer requirements, GlySure has set the foundation for its European clinical trials.
San Diego, CA January 8, 2013 – Ridge Diagnostics, Inc., a neurodiagnostic company, announced that Lonna J. Williams, CEO, will speak at the 6th Annual OneMedForum San Francisco 2013, to be held at The Sir Francis Drake Hotel on January 8, 2013 at 2:10pm.
Cognoptix, presenting at the 6th Annaul OneMedForum, January 7-9 in San Francisco, is a privately held medical device company creating and developing a simple, innovative non-invasive eye scanning test for the early detection and diagnosis of Alzheimer’s Disease.
Copyright © 2024 | WordPress Theme by MH Themes